UNSPSC 51412102: Buterizine

This classification denotes a vasodilating agent with the molecular formula C31H38N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N8516V0WOM, chemically known as 1h-benzimidazole, 2-butyl-5-((4-(diphenylmethyl)-1-piperazinyl)methyl)-1-ethyl but generally known as buterizine, which bears US NIH Compound Identifier 189902. European Medicines Agency schedules Buterizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06013MIG. The term BUTERIZINE is an International Non-Proprietary Name.

UNSPSC 51412102 Buterizine is a Commodity code representing pharmaceutical active ingredients and formulations procured by state and local health agencies, emergency services, and cooperative purchasing alliances for direct use in patient care and public health programs. State and local governments under this code buy emergency medications, generic pharmaceuticals, and over-the-counter products supplied through established pharmaceutical wholesalers and direct manufacturer channels, with procurement driven by standardized dosage requirements, FDA compliance, expiration-date management, and cost-containment strategies aligned with state health benefit programs. Issuing bodies include city fire and rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances. The City of Tampa's Fire Rescue procurement exemplifies direct municipal demand for emergency life support medications, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and the Texas Health and Human Services Commission represent coordinated state-level and interstate purchasing vehicles consolidating demand across multiple jurisdictions and facilities.

Recent activity spans Florida, Minnesota, Oregon, and Texas. The City of Tampa issued IFB 26P00188 on April 24, 2026, with response deadline April 8, 2026, seeking 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year term plus renewal and extension options; the solicitation includes a 5 percent SLBE bid discount capped at $10,000. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, with response deadline March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with contract effectiveness July 1, 2026, and a two-year initial term. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, seeking market intelligence on direct-to-manufacturer prescription programs to inform future formal procurement strategy rather than committing to specific contract values or timelines at the RFI stage.